Other languages Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.34 ^USD	-0.01%		+1.89%	-4.29%

Apr. 23	Transcript : Artelo Biosciences, Inc. - Special Call
Apr. 23	Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy	Apr. 23
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Top Premarket Gainers	Feb. 06
Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy	Jan. 23
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023	Nov. 02
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Artelo Biosciences Files $75 Million Mixed Shelf	23-07-07
Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11	23-06-07
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss	23-02-02
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08
Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5	22-08-16
Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09
Artelo Biosciences Enrolls First Three Cohorts in Cancer-Related Anorexia, Weight-Loss Study	22-07-19
Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13	22-07-19
Artelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12
Artelo Says ART27.13 Shows Positive Pre-Clinical Results in Protecting Muscles From Cancer-Linked Degeneration; Shares Surge	22-04-13
Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia	22-04-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Other languages

Filters